Polymyxins: Wisdom does not always come with age

Clinical Infectious Diseases

Volumn 57, Issue 6, 2013, Pages 877-883

  Kassamali, Zahra ^a   Rotschafer, John C ^b   Jones, Ronald N ^c   Prince, Randall A ^d   Danziger, Larry H ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c JMI LABORATORIES   (United States)

^d UNIVERSITY OF HOUSTON   (United States)

Author keywords

microbial sensitivity tests; polymyxins pharmacology; polymyxins therapeutic use

Indexed keywords

COLISTIMETHATE; COLISTIN; PENICILLIN DERIVATIVE; POLYMYXIN B; POLYMYXIN DERIVATIVE; POLYSORBATE 80;

AGAR DIFFUSION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERIAL INFECTION; BACTERIAL MEMBRANE; BACTERICIDAL ACTIVITY; BROTH DILUTION; COMPARATIVE STUDY; DISK DIFFUSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG MANUFACTURE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG QUALITY; FERMENTATION; GRAM NEGATIVE INFECTION; HUMAN; KIDNEY CLEARANCE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PAENIBACILLUS POLYMYXA; PRESCRIPTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUALITY CONTROL; REVIEW; STEADY STATE;

MICROBIAL SENSITIVITY TESTS; POLYMYXINS/PHARMACOLOGY; POLYMYXINS/THERAPEUTIC USE;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; POLYMYXINS;

EID: 84883255336     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit367     Document Type: Review

References (41)

1. Gould SJ. Morton's ranking of races by cranial capacity. Science 1978; 200:503-9.
2. Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. Clin Microbiol Rev 2008; 21:449-65.
3. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001; 39:183-90.
4. Barnett M, Bushby SRM, Wilkinson S. Sodium sulphomethyl derivatives of polymyxins. Brit J Pharmacol 1964; 23:552-74.
5. Thomas AH, Thomas JM, Holloway I. Microbiological and chemical analysis of polymyxin B and polymyxin E (colistin) sulphates. Analyst 1980; 105:1068-1076.
6. Brownlee G, Bushby SRM, Short EI. The chemotherapy and pharmacology of the polymyxins. Brit J Pharmacol 1952; 7:170-188.
7. Orwa JA, Van Gerven A, Roets E, Hoogmartens J. Liquid chromatography of polymyxin B sulphate. J Chromatogr A 2000; 870:237-243.
8. Polymyxin B [Package Insert]. Schaumburg, IL: Sagent Pharmaceuticals, 2011.
9. Orwa JA, Govaerts C, Busson R, et al. Isolation and structural characterization of colistin components. J Antibiot (Tokyo) 2001; 54: 595-599.
10. Colomycin [Package Insert]. Dartford, Kent: Forest Laboratories, 2010.
11. Coly-Mycin M [Package Insert]. Rochester, MN: JHP Pharmaceuticals, 2011.
12. Li J, Nation RL, Turnridge JD. Defining the dosage units for colistin methanesulfonate: urgent need for international harmonization. Antimicrob Agents Chemother 2006; 50:4231-2.
13. Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55:3284-94.
14. Dalfino L, Puntillo F, Mosca A, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 2012; 54:1720-9.
15. Sobieszcyzk ME, Furuya EY, Hay CM, et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant gram-negative respiratory tract infections. J Antimicrob Chemother 2004; 54:566-9.
16. He J, Ledesma KR, Lam W, et al. Variability of polymyxin B major components in commercial formulations. Int J Antimicrob Agents 2010; 35:308-10.
17. Nambiar S, Madurawe RD, Zuk SM, et al. Product quality of parenteral vancomycin products in the United States. Antimicrob Agents Chemother 2012; 56:2819-23.
18. Stansly PG, Schlosser ME. Studies on polymyxin: an agar diffusion method of assay. J Bacteriol 1947; 54:585-97.
19. Lightbown JW, Thomas AH, Grab B, Outschoorn AS. The second international standard for polymyxin B. Bull World Health Organ 1973; 48:85-90.
20. Lightbown JW, Bond JM, Grab B. The international standard for colistin. BullWorld Health Organ 1973; 48:65-74.
21. Lightbown JW, Bond JM, Grab B. The international reference preparation of colistin methane sulfonate. Bull World Health Organ 1973; 48:75-80.
22. The United States Pharmacopeia 35/National Formulary Available at: http://www.uspnf.com/uspnf/pub/index?usp=35&nf=30&s=2&offi cialOn=December%201,%202012. Accessed 3 December 2012.
23. The United States Pharmacopeia. Polymyxin B USP Certificate. Rockville, MD: USP, 2008. Available at: http://www.usp.org/pdf/EN/ref erenceStandards/ certificates/1547007-L0H010.pdf. Accessed 1 October 2012.
24. Turnidge JD, Bell JM. Antimicrobial susceptibility on solid media. In: Lorian V, ed. Antibiotics in laboratory medicine. Philadelphia, PA: LippincottWilliams & Wilkins, 2005.
25. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI document M100-S23.Wayne, PA: CLSI, 2013.
26. Swenson JM, Killgore GE, Tenover FC. Antimicrobial susceptibility testing of Acinetobacter spp. by NCCLS broth microdilution and disk diffusion methods. J Clin Microbiol 2004; 42:5102-08.
27. He H, Li C, Jacob J, et al. Pharmacokinetics (PK) of different brands of colistin methanesulfonate (CMS) in rats [abstract A1-662]. In: Program and abstracts of the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (Boston). Washington, DC: American Society of Microbiology, 2010.
28. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests. NCCLS Publication; Vol. 1, No. 6 (First Suppl to M02-A2), 1981.Wayne, PA: CLSI.
29. Ullman MA, Hovde LB, Rotschafer JC. Discordance between broth microdilution and Etest in determining colistin MIC values for Pseudomonas aeruginosa [abstract 1469]. In Program and abstracts of the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (Boston).Washington, DC: American Society of Microbiology, 2010.
30. Sader HS, Rhomberg PR, Flamm RK, Jones RN. Use of a surfactant (polysorbate-80) to improve MIC susceptibility testing results for polymyxin B and colistin. Diagn Microbiol Infect Dis 2012; 74:412-4.
31. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob Agents Chemother 2003; 47:1364-70.
32. Abdelraouf A, He K, Ledesma KR, Hu M, Tam VH. Pharmacokinetics and renal disposition of polymyxin B in an animal model. Antimicrob Agents Chemother 2012; 56:5724-7.
33. Dudhani RV, Turnidge JD, Coulthard K, et al. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 2010; 54:1117-24.
34. Li J, Milne RW, Nation RL, et al. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 2004; 53:837-40.
35. Li J, Coulthard K, Milne R, et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 2003; 52:987-99.
36. Markou N, Markantonis SL, Dimitrakis E, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multi-drug resistant gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 2008; 30: 143-51.
37. Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulphonate and colistin after intravenous administration in critically ill patients with gram-negative bacterial infections. Antimicrob Agents Chemother 2009; 53:3430-6.
38. Huang J, Tang Y, Sun J. Intravenous colistin sulfate: a rarely used form of polymyxin E for the treatment of severe multidrug-resistant gramnegative bacterial infections. Scand J Infect Dis 2010; 42:260-5.
39. Tam VH, Cau H, Ledesma KR, Hu M. In vitro potency of various polymyxin B components. Antimicrob Agents Chemother 2011; 55:4490-1.
40. Kwa A, Lim T, Low J, et al. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant gram-negative bacterial infections. Diagn Microbiol Infect Dis 2008; 60:163-7.
41. Zavascki AP, Goldani LZ, Cao G, et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 2008; 47:1298-304.